Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Breast Cancer

  Free Subscription


Articles published in Cancer Epidemiol Biomarkers Prev

Retrieve available abstracts of 99 articles:
HTML format



Single Articles


    January 2026
  1. WANG SS, Wu J, Wu AH, Cheng I, et al
    Associations of Proximity to Superfund Sites and Air Pollution with Breast Cancer Subtypes: Clues from a Case-Case Study and Call for Longitudinal Studies.
    Cancer Epidemiol Biomarkers Prev. 2026;35:7-9.
    PubMed     Abstract available


  2. MOONEY SJ, Rundle AG
    Can We Interpret Analyses of Etiologic Heterogeneity When Molecular Markers Are Used to Classify Tumors?
    Cancer Epidemiol Biomarkers Prev. 2026;35:138-143.
    PubMed     Abstract available


    December 2025
  3. ZHANG Z, Ray RM, An R, Klonoff-Cohen HS, et al
    Mammographic Density as a Mediator for Breast Cancer Risk: Pooled Analysis of Four Population-Based Case-Control Studies on Women with Screening Mammograms Under 50.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  4. LUI ML, Lee Argov EJ, Kehm RD, Karr AG, et al
    Social Drivers of Guideline- Discordant Breast Cancer Screening by Age and Mortality Risk.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  5. LI X, Shan Y, Yu Y, Zhang D, et al
    Negative emotions and breast cancer risk for women with benign breast disease: a prospective multicenter cohort study in China.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  6. VAN ALSTEN SC, Love MI, Calhoun BC, Butler EN, et al
    Identifying locally recurrent versus second primary breast cancer: Genomic versus clinical criteria from Carolina Breast Cancer Study Phase III.
    Cancer Epidemiol Biomarkers Prev. 2025 Dec 1. doi: 10.1158/1055-9965.EPI-25-1298
    PubMed     Abstract available


  7. CASTON NE, Spees LP, Waters AR, Wheeler SB, et al
    Associations between Insurance Status, Financial Hardship, and Rurality on Receipt of Guideline-Concordant Mammography.
    Cancer Epidemiol Biomarkers Prev. 2025;34:2150-2157.
    PubMed     Abstract available


  8. MCVICKER L, Gunathilake KAMP, Cardwell CR, Kunzmann AT, et al
    Metabolic Syndrome and the Risk of Breast, Endometrial, and Ovarian Cancer among Postmenopausal Women in the UK Biobank.
    Cancer Epidemiol Biomarkers Prev. 2025;34:2125-2134.
    PubMed     Abstract available


    November 2025
  9. SHARIFF-MARCO S, Von Behren J, Chirikova E, Inamdar PP, et al
    Assessing upstream structural and social drivers of health in breast cancer survivorship: the Pathways Study Neighborhood Resource.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  10. NASH SH, Loeffler BT, Verhage E, Sorensen J, et al
    Comorbidities among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results-Medicare Study.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1914-1923.
    PubMed     Abstract available


    October 2025
  11. OBENG-GYASI S, Handley D, Plascak JJ, Anampa JD, et al
    Neighborhood Contexts and Healthcare Utilization in Patients with Breast Cancer Receiving Chemotherapy.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  12. EL MOHEB M, Shen C, Rabinovich E, Kim S, et al
    Predicting Health-Related Quality of Life Trajectories in Elderly Breast Cancer Patients: From Pre-Diagnosis to Long-Term Follow-up.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  13. PINHEIRO LC, Reeder-Hayes KE
    The Honest Broker: Reimagining the Roles of Health Services Research, Community Partnership, and Policymaking to Address Structural Determinants of Cancer Outcomes.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1683-1685.
    PubMed     Abstract available


  14. AL HASAN SM, Toriola AT
    Prevalence and Determinants of Mammography Use among Women Aged 40 to 49 Years in the United States.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1759-1770.
    PubMed     Abstract available


  15. HOLOWATYJ AN, Liu L, Munro HM, Perkins-Smith JJ, et al
    Income, Race, and Survival among Low-Income Black and White Americans with Lung, Breast, Prostate, or Colorectal Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1749-1758.
    PubMed     Abstract available


  16. TIMBRES J, Kohut K, Mavaddat N, Easton DF, et al
    Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


    September 2025
  17. WANG X, Yang X, Chen R, Liu W, et al
    Aspirin Use and Risk of Breast Cancer Recurrence in Chinese Patients.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  18. CHEN JH, Slack Tidwell RS, Kai M, Lucci A, et al
    Impact of Postpartum Diagnosis on Survival of Women with Inflammatory Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  19. KIM EY, Shin S, Chang Y, Ryu S, et al
    Serum Ferritin and Iron-Related Biomarkers in Relation to Breast Cancer Risk by Menopausal Status: A Prospective Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2025 Sep 8. doi: 10.1158/1055-9965.EPI-25-0923
    PubMed     Abstract available


  20. CHOI HL, Jung W, Youn J, Kim B, et al
    Risk of Parkinson's Disease Among Breast Cancer Survivors: A Nationwide Cohort Study in South Korea.
    Cancer Epidemiol Biomarkers Prev. 2025 Sep 4. doi: 10.1158/1055-9965.EPI-25-0712
    PubMed     Abstract available


    August 2025
  21. ABDOLLAHPOUR I, Darouei B, Amani-Beni R, Yazdi M, et al
    Lifetime Sunlight Exposure and Risk of Breast Cancer: A Population-based incident Case-Control Study.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  22. DONZELLA SM, Rogers M, O'Brien KM, Von Holle A, et al
    Sedentary time and breast cancer risk in the Sister Study Cohort.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  23. TELONIS AG, Hernandez AE, Borowsky PA, Reguero Hernandez ED, et al
    Molecular Portraits of Social Adversity in Breast Cancer: Neighborhood Disadvantage is Associated with Epigenetic Deregulation of Key Oncogenic Pathways.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  24. BOROWSKY PA, Nahodyl L, Sable S, Sierra MA, et al
    Residential Proximity to NPL Superfund Sites and High Particulate Matter Exposure is Associated with Increased Likelihood of Triple Negative Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  25. LOEHRER EA, van der Baan FH, Mooij TM, Andrieu N, et al
    Breast Density Changes after Risk-Reducing Salpingo-oophorectomy in Women with a Pathogenic Germline Variant in BRCA1 or BRCA2.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1295-1305.
    PubMed     Abstract available


  26. YAGHJYAN L, Tamimi RM, Baker GM, Heng YJ, et al
    Associations of Stem Cell Markers with Lobular Involution in Benign Breast Tissue.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1314-1321.
    PubMed     Abstract available


  27. CARROLL JE, Guard HE, March D, Arcaro KF, et al
    Urinary Levels of Endocrine-Disrupting Chemicals and Breast Density in Young Women.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1306-1313.
    PubMed     Abstract available


    July 2025
  28. ALVAREZ SOTO A, Gan W, Tannenbaum S
    Racial Disparities in Pathologic Complete Response and Survival after Neoadjuvant Chemotherapy for Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  29. FOWLER ME, Reeves HD, Smith MJ, Saini G, et al
    Structural determinants of racial disparities in breast cancer survival in Alabama.
    Cancer Epidemiol Biomarkers Prev. 2025 Jul 9. doi: 10.1158/1055-9965.EPI-25-0195
    PubMed     Abstract available


  30. NAIR NM, Mendicino L, Fiorica PN, Omilian AR, et al
    The African-specific variant in the Duffy Antigen Receptor for Chemokines (DARC) gene, CD8+ T-cell density and Aggressive Breast Cancer Subtypes in Black Women.
    Cancer Epidemiol Biomarkers Prev. 2025 Jul 8. doi: 10.1158/1055-9965.EPI-25-0454
    PubMed     Abstract available


  31. LAMBERT PC, Andersson TML, Myklebust TA, Moller B, et al
    Monitoring Temporal Trends in Cancer Survival: Choosing Appropriate Standards When Accounting for Age and Other-Cause Mortality Variation Over Time.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1141-1148.
    PubMed     Abstract available


    June 2025
  32. TAUB CJ, Hernandez AE, Borowsky PA, Ream M, et al
    Distinct Sources of Social Adversity, Stress, and Coping Mechanisms Among Breast Cancer Patients to Identify Areas for Intervention.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  33. FRITSCH-HUMBLET B, Jiao Y, Eon-Marchais S, Dondon MG, et al
    Body mass index, IGF1-related polymorphisms and risk of familial breast cancer in women with no BRCA1 or BRCA2 pathogenic variant.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  34. READING JM, Solk P, Starikovsky J, Song J, et al
    Effects of a Physical Activity mHealth Intervention (Fit2Thrive) on WCRF/AICR Cancer Prevention Score among Breast Cancer Survivors: A Secondary Data Analysis.
    Cancer Epidemiol Biomarkers Prev. 2025 Jun 9. doi: 10.1158/1055-9965.EPI-25-0167
    PubMed     Abstract available


  35. MCTIERNAN A
    Lifestyle and Breast Cancer Risk: How Does It All Add Up?
    Cancer Epidemiol Biomarkers Prev. 2025;34:833-835.
    PubMed     Abstract available


  36. FENLON J, Van Bibber N, Mahlow J, Yamoah K, et al
    Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers.
    Cancer Epidemiol Biomarkers Prev. 2025;34:860-867.
    PubMed     Abstract available


  37. KELLY RL, Liu Y, Harris AR, Peng C, et al
    The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages.
    Cancer Epidemiol Biomarkers Prev. 2025;34:868-874.
    PubMed     Abstract available


    May 2025
  38. WILSON OW, Matthews CE, Wojcik KM, Tarasenko YN, et al
    The Effects of Post-Diagnosis Recreational Aerobic Exercise among Breast Cancer Survivors: A Systematic Review/Meta-Analyses.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  39. AOKI RL, Alexeeff SE, Caan BJ, Kushi LH, et al
    Nativity and Healthy Lifestyle Index in a Pooled Cohort of Female Breast Cancer Survivors from Northern California.
    Cancer Epidemiol Biomarkers Prev. 2025 May 7. doi: 10.1158/1055-9965.EPI-24-1871
    PubMed     Abstract available


    April 2025
  40. DUNN MR, Niu H, Li D, Emerson MA, et al
    Applying a novel measure of community-level healthcare access to assess breast cancer care timeliness.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  41. BERGIN ART, Te Marvelde L, Milne RL, Lara Gonzalez LE, et al
    Aboriginal and Torres Strait Islander females and survival from breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  42. TANG L, Wang Z, Hsiao HH, Kwan ML, et al
    Associations of Cruciferous Vegetable Intake with Breast Cancer Survival in a Diverse Population in the Pathways Study.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  43. ROHAN TE, Zhang C, Wang Y, Couch FJ, et al
    p16, COX-2, and Ki67 protein expression in DCIS and risk of ipsilateral invasive breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  44. VERDIESEN RMG, Shokouhi M, Burgess S, Canisius S, et al
    Causal effects of breast cancer risk factors across hormone receptor breast cancer subtypes: A two-sample Mendelian randomization study.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  45. LIMA SM, Palermo TM, Lee FF, Insaf TZ, et al
    Historical redlining and all-cause survival after breast cancer diagnosis.
    Cancer Epidemiol Biomarkers Prev. 2025 Apr 3. doi: 10.1158/1055-9965.EPI-24-1862
    PubMed     Abstract available


  46. QIN B, Vyas M, Moore SC, Su X, et al
    Reproducibility of Plasma Metabolome Over 1 Year in a Population-based Cohort of Black Breast Cancer Survivors.
    Cancer Epidemiol Biomarkers Prev. 2025 Apr 3. doi: 10.1158/1055-9965.EPI-24-1646
    PubMed     Abstract available


  47. MCDONALD JA
    Unveiling the Stroma: Reproductive Factors and the Tumor Microenvironment in African Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025;34:459-461.
    PubMed     Abstract available


    March 2025
  48. OGBENNA BT, He X, Wu AH, Le Marchand L, et al
    Healthy Lifestyle Index and Breast Cancer Risk among Postmenopausal Women: The Multiethnic Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  49. DAVIS S, Lian M, Colditz GA, Davis KL, et al
    Racialized Economic Segregation, Treatment and Outcomes in Women with Triple-Negative Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  50. REN Y, Maselko J, Tan X, Olshan AF, et al
    PATTERNS OF CHANGE IN EMOTIONAL AND FUNCTIONAL WELL-BEING FOLLOWING BREAST CANCER DIAGNOSIS.
    Cancer Epidemiol Biomarkers Prev. 2025 Mar 4. doi: 10.1158/1055-9965.EPI-24-0849
    PubMed     Abstract available


  51. ALBERS FEM, Dashti SG, Lynch BM
    Epidemiologic Studies of Biomarkers and Their Role in Carcinogenesis: The Need for a Formal Causal Inference Approach.
    Cancer Epidemiol Biomarkers Prev. 2025;34:373-374.
    PubMed     Abstract available


    February 2025
  52. PLASCAK JJ, Xing CY, Mooney SJ, Rundle AG, et al
    Neighborhood disinvestment predicts shorter cancer survival time among Black women diagnosed with invasive breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  53. SCHROTH W, Murdter TE, Schwab M
    Unraveling the Impact of Drug Metabolism on Tamoxifen Response in Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025;34:221-223.
    PubMed     Abstract available


    January 2025
  54. WALKER B, Pollard E, Howard SP, Jones VM, et al
    The Role of Race/Ethnicity on the Association between Neighborhood Deprivation and Breast Cancer Outcomes among Kentucky Breast Cancer Patients years 2010-2022.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  55. HERNANDEZ AE, Borowsky PA, Nahodyl L, Pinheiro PS, et al
    A Neighborhood-Level Hispanic Paradox: the Interaction between Hispanic Density, Neighborhood Disadvantage, and Survival in Breast Cancer Patients.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  56. ALBERS FE, Swain CT, Lou MW, Dashti SG, et al
    Insulin and insulin-like growth factor and risk of postmenopausal estrogen receptor-positive breast cancer: a case-cohort analysis.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed     Abstract available


  57. MAVADDAT N, Ficorella L, Carver T, Lee A, et al
    Correction: Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model.
    Cancer Epidemiol Biomarkers Prev. 2025;34:205.
    PubMed    


  58. ANAMPA JD, Lin S, Obeng-Gyasi S, Xue X, et al
    Treatment and Survival Differences between Patients with Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma of the Breast.
    Cancer Epidemiol Biomarkers Prev. 2025;34:125-132.
    PubMed     Abstract available


    December 2024
  59. HUANG X, Lott PC, Hu D, Zavala VA, et al
    Evaluation of multiple breast cancer polygenic risk score panels in women of Latin American heritage.
    Cancer Epidemiol Biomarkers Prev. 2024 Dec 3. doi: 10.1158/1055-9965.EPI-24-1247
    PubMed     Abstract available


  60. POURALI G, Toriola AT
    The Untapped Opportunities of Addressing Lifecourse Growth in Mammographic Breast Density and Breast Cancer Prevention in Non-Hispanic Black Women.
    Cancer Epidemiol Biomarkers Prev. 2024;33:1541-1543.
    PubMed     Abstract available


  61. NABI O, Liu Y, Struthers J, Lian M, et al
    The Role of Residential Segregation in Treatment and Outcomes of Ductal Carcinoma In Situ of the Breast.
    Cancer Epidemiol Biomarkers Prev. 2024;33:1633-1639.
    PubMed     Abstract available


  62. BIGHAM Z, Holder EX, Rodday AM, Breeze JL, et al
    Lifecourse Growth and Development Determinants of Mammographic Density in Black Women.
    Cancer Epidemiol Biomarkers Prev. 2024;33:1640-1650.
    PubMed     Abstract available


    November 2024
  63. DENG Z, Visvanathan K
    Patterns of subsequent cancer incidence over time in patients with breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  64. MACLEHOSE RF, Ahern TP, Collin LJ, Li A, et al
    CYP2D6 Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  65. KOKA H, Tian Y, Deng L, Yu K, et al
    Mammographic density in relation to breast cancer risk factors among Chinese women.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  66. LORONA NC, Othus M, Malone KE, Linden HM, et al
    Metabolic syndrome and risks of breast cancer outcomes for luminal, triple-negative, and HER2-overexpressing subtypes.
    Cancer Epidemiol Biomarkers Prev. 2024 Nov 1. doi: 10.1158/1055-9965.EPI-24-1167
    PubMed     Abstract available


  67. CURRO II, Teasdale CA, Wyatt LC, Foster V, et al
    Cancer Screening, Knowledge, and Fatalism among Chinese, Korean, and South Asian Residents of New York City.
    Cancer Epidemiol Biomarkers Prev. 2024;33:1475-1483.
    PubMed     Abstract available


    October 2024
  68. KEHM RD, Genkinger JM, Knight JA, Maclnnis RJ, et al
    Physical activity during adolescence and early adulthood and breast cancer risk before age 40 years.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  69. ASHAD-BISHOP KC, Star J, Giaquinto AN, Smith RA, et al
    Changes in Breast Cancer Screening Prevalence in the US During the COVID-19 Pandemic, 2018-2022.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  70. SARMIENTO DD, Tumas N, Pereyra SA, Scruzzi GF, et al
    Social determinants of breast cancer screening: a multilevel analysis of proximal and distal factors related to the practice of mammography.
    Cancer Epidemiol Biomarkers Prev. 2024 Oct 3. doi: 10.1158/1055-9965.EPI-24-1001
    PubMed     Abstract available


  71. MARCUS POST L, Pathak DR, Hamilton AS, Hirko KA, et al
    Adiposity throughout Adulthood and Risk of Young Onset Breast Cancer Tumor Subtypes in the Young Women's Health History Study.
    Cancer Epidemiol Biomarkers Prev. 2024 Oct 2. doi: 10.1158/1055-9965.EPI-24-1067
    PubMed     Abstract available


  72. WOOF VG, Howell A, Fox L, McWilliams L, et al
    Are women's breast cancer risk appraisals in line with updated clinical risk estimates communicated? Results from a UK Family History Risk and Prevention Clinic.
    Cancer Epidemiol Biomarkers Prev. 2024 Oct 2. doi: 10.1158/1055-9965.EPI-24-0581
    PubMed     Abstract available


  73. ARANDA-GUTIERREZ A, Soto-Perez-de-Celis E
    The Disconnect between Clinical Guidelines and Reality: The Case of Trastuzumab.
    Cancer Epidemiol Biomarkers Prev. 2024;33:1259-1260.
    PubMed     Abstract available


  74. ABE JV, Legaspi J, Guillermo C, Bogumil D, et al
    Breast, Colorectal, and Prostate Cancer Incidence among Filipino Americans by Generational Status in the Multiethnic Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2024;33:1311-1317.
    PubMed     Abstract available


    September 2024
  75. WOJCIK KM, Wilson OWA, Shiels MS, Sheppard VL, et al
    Racial, Ethnic, and Socioeconomic Disparities in Meeting Physical Activity Guidelines among Female Breast Cancer Survivors in the United States.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  76. KALIA SS, Boddicker NJ, Yadav S, Huang H, et al
    Development of a breast cancer risk prediction model integrating monogenic, polygenic, and epidemiologic risk.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


    August 2024
  77. BRANTLEY KD, Ziegler RG, Craft NE, Hankinson SE, et al
    Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses' Health Study.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  78. PARK GE, Kim SH, Han K
    A Large Cohort Study of Height and Mammographic Density in Relation to Breast Cancer Risk among Korean Women.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  79. SINGH RK, Getz KR, Kyeyune JK, Jeon MS, et al
    Aspirin Metabolites and Mammographic Breast Density in Premenopausal Women.
    Cancer Epidemiol Biomarkers Prev. 2024;33:1126-1128.
    PubMed     Abstract available


    July 2024
  80. BHIMANI J, O'Connell K, Persaud S, Blinder V, et al
    Patient characteristics associated with intended non-guideline chemotherapy in women with stage I-IIIA breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  81. ANG BH, Teo SH, Ho WK
    Systematic review and meta-analysis of lifestyle and reproductive factors associated with risk of breast cancer in Asian women.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  82. NORRIS RP, Dew R, Greystoke A, Cresti N, et al
    Socio-demographic disparities in HER2+ breast cancer trastuzumab receipt: An English population-based study.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  83. ABUBAKAR M, Ahearn TU, Duggan MA, Lawrence S, et al
    Contribution of pre-diagnostic host factors to shaping the stromal microenvironment of breast cancer among sub-Saharan African women.
    Cancer Epidemiol Biomarkers Prev. 2024 Jul 3. doi: 10.1158/1055-9965.EPI-24-0390
    PubMed     Abstract available


  84. OH H, Yaghjyan L, Heng YJ, Rosner B, et al
    Associations of Early-Life and Adult Anthropometric Measures with the Expression of Stem Cell Markers CD44, CD24, and ALDH1A1 in Women with Benign Breast Biopsies.
    Cancer Epidemiol Biomarkers Prev. 2024;33:933-943.
    PubMed     Abstract available


    June 2024
  85. LOHANI KR, Nibbe AM, Vierkant RA, Pacheco-Spann LM, et al
    Understanding benign breast disease and subsequent breast cancer in Hispanic white females; a step closer to evidence-based management.
    Cancer Epidemiol Biomarkers Prev. 2024 Jun 5. doi: 10.1158/1055-9965.EPI-24-0204
    PubMed     Abstract available


  86. YAGHJYAN L, Wang Z, Warner ET, Rosner B, et al
    Reproductive Factors Related to Childbearing and a Novel Automated Mammographic Measure, V.
    Cancer Epidemiol Biomarkers Prev. 2024;33:804-811.
    PubMed     Abstract available


    May 2024
  87. YE Z, Nguyen TL, Dite GS, Maclnnis RJ, et al
    Mammographic texture versus conventional Cumulus measure of density in breast cancer risk prediction: a literature review.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  88. FREEMAN JQ, Huo D
    Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities?
    Cancer Epidemiol Biomarkers Prev. 2024;33:635-637.
    PubMed     Abstract available


  89. JATOI I
    Breast Cancer Screening: Can We Justify Deescalation?
    Cancer Epidemiol Biomarkers Prev. 2024;33:638-640.
    PubMed     Abstract available


  90. PARK JE, Smith MA, Van Alsten SC, Walens A, et al
    Diffsig: Associating Risk Factors with Mutational Signatures.
    Cancer Epidemiol Biomarkers Prev. 2024;33:721-730.
    PubMed     Abstract available


  91. VAN ALSTEN SC, Dunn MR, Hamilton AM, Ivory JM, et al
    Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status.
    Cancer Epidemiol Biomarkers Prev. 2024;33:654-661.
    PubMed     Abstract available


    April 2024
  92. PARADA H, Wu T, Hoh E, Rock CL, et al
    Red Blood Cell Polyunsaturated Fatty Acids and Mortality Following Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  93. COLLISTER JA, Liu X, Littlejohns TJ, Cuzick J, et al
    Assessing the value of incorporating a polygenic risk score with non-genetic factors for predicting breast cancer diagnosis in the UK Biobank.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


  94. MOSS JL, Geyer NR, Lengerich EJ
    Patterns of Cancer-Related Healthcare Access across Pennsylvania: Analysis of Novel Census Tract-Level Indicators of Persistent Poverty.
    Cancer Epidemiol Biomarkers Prev. 2024;33:616-623.
    PubMed     Abstract available


  95. BARBER LE, McCullough LE, Johnson DA
    Eyes Wide Open: Sleep as a Potential Contributor to Racial and Ethnic Disparities in Cancer.
    Cancer Epidemiol Biomarkers Prev. 2024;33:471-479.
    PubMed     Abstract available


  96. HAN E, Van Horn L, Snetselaar L, Shepherd JA, et al
    The Associations between Intakes of One-Carbon Metabolism-Related Vitamins and Breast Density among Young Women.
    Cancer Epidemiol Biomarkers Prev. 2024;33:567-575.
    PubMed     Abstract available


    March 2024
  97. SIEGEL SD, Zhang Y, Lynch SM, Rowland J, et al
    A Novel Approach for Conducting a Catchment Area Analysis of Breast Cancer by Age and Stage for a Community Cancer Center.
    Cancer Epidemiol Biomarkers Prev. 2024 Mar 7. doi: 10.1158/1055-9965.EPI-23-1125
    PubMed     Abstract available


  98. LEE M, Kotake R, Yamauchi H
    Physical Activity and Mammographic Density in Japanese Women.
    Cancer Epidemiol Biomarkers Prev. 2024;33:365-370.
    PubMed     Abstract available


    February 2024
  99. FARBER R, Houssami N, McGeechan K, Barratt A, et al
    Breast cancer stage and size detected with film versus digital mammography in New South Wales, Australia: a population-based study using routinely collected data.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.